Gastroenterology
Volume 129, Issue 3 , Pages 807-818, September 2005

A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s Disease

Presented in part at the American Gastroenterological Association Digestive Disease Week (Orlando, Florida, May 17–22, 2003), the American College of Gastroenterology 68th Annual Scientific Meeting (Baltimore, Maryland, October 10–15, 2003), and the United European Gastroenterology Week (Madrid, Spain, November 1–5, 2003).

  • Stefan Schreiber

      Affiliations

    • Hospital for General Internal Medicine, Christian-Albrechts University, Klinik für Allgemeine Innere Medizin, Kiel, Germany
    • Institute for Clinical Molecular Biology, Christian-Albrechts University, Klinik für Allgemeine Innere Medizin, Kiel, Germany
    • Corresponding Author InformationAddress requests for reprints to: Stefan Schreiber, MD, Christian-Albrechts University, Klinik für Allgemeine Innere Medizin, Schittenhelmstrasse 12, Kiel 24105, Germany.fax: (49) 431-597-1842
    • ,
  • Paul Rutgeerts

      Affiliations

    • University Hospital Leuven, Gastroenterology, Leuven, Belgium
    • ,
  • Richard N. Fedorak

      Affiliations

    • University of Alberta, Division of Gastroenterology, Edmonton, Alberta, Canada
    • ,
  • Munaa Khaliq–Kareemi

      Affiliations

    • Dalhousie University, Halifax, Nova Scotia, Canada
    • ,
  • Michael A. Kamm

      Affiliations

    • St Mark’s Hospital, London, United Kingdom
    • ,
  • Michel Boivin

      Affiliations

    • Hôpital St Luc, Montreal, Canada
    • ,
  • Charles N. Bernstein

      Affiliations

    • University of Manitoba, Winnipeg, Canada
    • ,
  • Michael Staun

      Affiliations

    • Department of Gastroenterology, Rigshospitalet, Copenhagen, Denmark
    • ,
  • Ole Østergaard Thomsen

      Affiliations

    • Department of Gastroenterology, Herlev Hospital, University of Copenhagen, Herlev, Denmark
    • ,
  • Alison Innes

      Affiliations

    • UCB Research and Development, Slough, Berkshire, United Kingdom
    • ,
  • CDP870 Crohn’s Disease Study Group

Received 14 September 2004; accepted 26 May 2005.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Supported by Celltech R&D, Ltd. The German Federal Ministry for Education and Research Competence Network “Inflammatory Bowel Disease” provided additional support with the organization of the trial. S.S., P.R., and O.Ø.T. have served as paid consultants to Celltech. A.I. was an employee of Celltech (now UCB).(www.ikmb.uni-kiel.de).

PII: S0016-5085(05)01352-1

doi:10.1053/j.gastro.2005.06.064

Refers to article:

  • C-Reactive Protein: Anti-Placebo or Predictor of Response

    James D. Lewis
    Gastroenterology September 2005 (Vol. 129, Issue 3, Pages 1114-1116)

Refers to erratum:

Gastroenterology
Volume 129, Issue 3 , Pages 807-818, September 2005

Article Tools

* Image Usage & Resolution